Table 1.
Baseline characteristics of study participants according to body mass index categories
| BMI <22 (n = 478) |
22–24.9 (n = 1561) |
25–29.9 (n = 5044) |
30–34.9 (n = 3600) |
35–39.9 (n = 1300) |
≥40 (n = 538) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics | N* | N* | N* | N* | N* | N* | P-value | ||||||
| BMI (kg/m2) | 20.5 (1.4) | 23.8 (0.8) | 27.6 (1.40) | 32.1 (1.4) | 37.0 (1.40) | 43.8 (3.8) | <0.0001 | ||||||
| Age (years) | 65.0 (8.9) | 64.7 (8.1) | 64.4 (7.8) | 62.9 (7.5) | 61.6 (7.4) | 60.2 (6.7) | <0.0001 | ||||||
| Males n (%) | 272 (56.9) | 1052 (67.4) | 5043 | 3594 (71.3) | 2312 (64.2) | 703 (54.1) | 203 (37.7) | <0.0001 | |||||
| Waist males (cm) | 272 | 82.2 (10.1) | 1049 | 89.6 (8.2) | 3587 | 97.8 (8.8) | 2311 | 108.2 (8.4) | 699 | 117.7 (10.2) | 199 | 128.1 ( 13.4) | <0.0001 |
| Hip males (cm) | 272 | 88.9 (9.1) | 1049 | 94.5 (8.7) | 3587 | 100.6 (8.6) | 2311 | 107.8 (9.0) | 699 | 115.6 ( 11.2) | 192 | 125.1 (14.2) | <0.0001 |
| Waist females (cm) | 206 | 77.2 (10.4) | 509 | 83.9 (10.6) | 1447 | 91.2 (9.3) | 1287 | 100.7 (9.1) | 596 | 108.4 (9.8) | 332 | 117.9 (11.0) | <0.0001 |
| Hip females (cm) | 206 | 88.3 (9.1) | 509 | 94.6 (9.2) | 1442 | 101.8 (9.3) | 1287 | 111.3 (9.1) | 595 | 120.0 (9.5) | 312 | 131.1 ( 10.8) | <0.0001 |
| Ever smoked n (%) | 230 (48.1) | 842 (53.9) | 3017 (59.8) | 2227 (61.9) | 745 (57.3) | 274 (50.9) | <0.0001 | ||||||
| Previous diabetes n (%) | 405 (84.7) | 1314 (84.2) | 5043 | 4145 (82.2) | 2892 (80.3) | 1095 (84.2) | 456 (84.8) | 0.0009 | |||||
| New diabetesa n (%) | 15 (3.1) | 85 (5.4) | 316 (6.3) | 241 (6.7) | 73 (5.6) | 28 (5.2) | 0.0312 | ||||||
| Diabetes duration years (SD) | 7.16 (7.57) | 6.14 (7.04) | 4.87 (5.97) | 4.28 (5.33) | 3.78 (4.57) | 3.72 (4.71) | <0.0001 | ||||||
| Previous CV event n (%) | 296 (61.9) | 960 (61.5) | 3178 (63.0) | 2084 (57.9) | 648 (49.8) | 204 (37.9) | <0.0001 | ||||||
| Hypertension n (%) | 309 (64.6) | 1124 (72.0) | 3906 (77.4) | 2980 (82.8) | 1152 (88.6) | 483 (89.8) | <0.0001 | ||||||
| SBP (mmHg) | 141.4 (24.4) | 144.1 (23.0) | 5043 | 145.3 (21.6) | 3598 | 146.9 (21.1) | 1298 | 147.7 (21.4) | 537 | 147.1 (22.1) | <0.0001 | ||
| DBP (mmHg) | 79.0 (11.7) | 81.2 (11.9) | 5041 | 83.3 ( 11.6) | 3596 | 85.4 (11.9) | 87.6 ( 12.1) | 88.3 ( 13.0) | <0.0001 | ||||
| LDL cholesterol (mmol/L) | 472 | 2.92 (1.05) | 1551 | 2.87 (1.03) | 4961 | 2.87 (1.03) | 3533 | 2.90 (1.04) | 1265 | 2.97 (1.1) | 532 | 3.02 (0.98) | 0.0028 |
| HbA1c (%) | 471 | 6.5 (0.96) | 1537 | 6.5 (1.0) | 4963 | 6.5 (1.0) | 3570 | 6.5 (0.9) | 1284 | 6.6 (0.93) | 534 | 6.6 (0.9) | 0.0158 |
| eCRF (mL/min/1.73 m2) | 79.5 (26.2) | 1560 | 77.2 (21.2) | 5037 | 76.9 (21.4) | 3595 | 77.1 (20.6) | 1299 | 78.5 (20.8) | 78.5 (21.8) | 0.0232 | ||
| Glargine allocation n (%) | 241 (50.4) | 756 (48.4) | 2587 (51.3) | 1766 (49.1) | 639 (49.2) | 262 (48.7) | 0.2271 | ||||||
| Omega 3 allocation n (%) | 248 (51.9) | 773 (49.5) | 2537 (50.3) | 3599 | 1787 (49.7) | 656 (50.5) | 271 (50.4) | 0.9381 | |||||
| Thiazide diuretic n (%) | 48 (10.0) | 220 (14.1) | 832 (16.5) | 764 (21.2) | 342 (26.3) | 163 (30.3) | <0.0001 | ||||||
| ACE-I or ARB n (%) | 279 (58.4) | 964 (61.8) | 3412 (67.6) | 2612 (72.6) | 989 (76.1) | 420 (78.1) | <0.0001 | ||||||
| Beta blocker n (%) | 178 (37.2) | 725 (46.4) | 2671 (53.0) | 2035 (56.5) | 718 (55.2) | 267 (49.6) | <0.0001 | ||||||
| Other BP drug n (%) | 117 (37.0) | 566 (36.3) | 1981 (39.3) | 1541 (42.8) | 601 (46.2) | 273 (50.7) | <0.0001 | ||||||
| Statin n (%) | 206 (43.1) | 815 (52.2) | 2827 (56.0) | 2012 (55.9) | 651 (50.1) | 225 (41.8) | <0.0001 | ||||||
| Antiplatelet drug n (%) | 318 (66.5) | 1085 (69.5) | 3583 (71.0) | 2522 (70.1) | 841 (64.7) | 310 (57.6) | <0.0001 | ||||||
Values are n (%) or mean (SD), N* number of patients if missing data, P-values for Log-rank test between categories. aNewly diagnosed diabetes at baseline. Previous CV event is defined according to the ORIGIN protocol as previous myocardial infarction, stroke or revascularization [15].